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ABSTRACT  
Introduction: Trimethoprim-sulfamethoxazole (TMP-SMX) is a commonly used antibiotic 
often associated with idiosyncratic adverse drug reactions (IADRs). Historically, bioactivation of 
SMX to a reactive intermediate has been implicated in IADRs.  Recently, the bioactivation of 
TMP has been described as TMP N-acetyl cysteine (NAC) adducts were identified following 
human liver microsome (HLM) incubations and in the urine of children taking TMP, suggesting 
cytochrome P450 enzymes (P450s) catalyze TMP bioactivation. In this study, we identified the 
P450s involved in the formation of six TMP primary metabolites.  
Methods: A panel of characterized HLMs (n=16), c-DNA expressed P450s, and pooled HLMs 
in the presence and absence of selective P450 inhibitors were incubated with therapeutic 
concentrations of TMP. Reactive metabolites were trapped with NAC, and metabolite formation 
was quantified by UPLC/MS/MS. Correlation coefficients between the rates of metabolite 
formation and P450 marker reaction rates were determined using least-squares regression 
analysis and evaluated at α=0.05.  
Results: 1-NO-TMP, Cα-NAC-TMP and Cα-OH-TMP were formed by CYP3A4 and inhibited 
by ketoconazole (CYP3A inhibitor). 4'-demethylation was catalyzed by several P450s including 
CYP3A4, correlated with multiple CYPs, and inhibited primarily with ketoconazole suggesting 
CYP3A4 contributed to 4'-demethylation. 3-NO-TMP was formed by CYP1A and inhibited by 
α-naphthoflavone (CYP1A inhibitor). 3'-demethylation was catalyzed by multiple P450s 
including CYP2C9, correlated with CYP2C9 activity and inhibited by sulphafenazole (CYP2C9 
inhibitor).  
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Conclusion: These findings suggest that P450s were responsible for the primary metabolism of 
TMP with CYPs 2C9 and 3A4 being the most significant contributors to TMP primary 
metabolism.  Factors modulating activity of these enzymes may affect the risk of IADRs.   
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INTRODUCTION 
Trimethoprim-sulfamethoxazole (TMP-SMX) is a frequently prescribed antimicrobial for 
the treatment of urinary tract, skin and soft tissue infections, and the prevention opportunistic 
infections in the immune-compromised host (Copp et al., 2011;  Hersh et al., 2008;  Mofenson et 
al., 2009). This drug combination is also one of the most common causes of unpredictable, 
undesired and potentially severe idiosyncratic adverse drug reactions (IADRs) that include rash, 
fever, lymphadenopathy, cytopenias, liver injury or severe skin detachment (Stevens Johnson 
Syndrome or toxic epidermal necrolysis) (Roujeau et al., 1995;  Clarkson and Choonara, 2002).  
Historically, SMX has been suspected as the inciting agent in these IADRs, largely based on its 
ability to form a nitroso intermediate capable of modifying proteins resulting in subsequent 
immunogenicity and antigenicity (Manchanda et al., 2002;  Naisbitt et al., 2002).  However, 
administration of TMP alone has also been associated with severe and even fatal IADRs 
(Hawkins et al., 1993;  Mortimer et al., 2005;  Nwokolo et al., 1988). We recently identified N-
acetyl cysteine (NAC) adducts of TMP metabolites in the urine of children taking TMP-SMX, 
confirming bioactivation in vivo, and raising the possibility that TMP may contribute to IADRs 
(van Haandel et al., 2014). Incubations containing human liver microsomes (HLMs), NAC and 
an NADPH-generating system formed all of the TMP-NAC adducts observed in urine, 
suggesting the possibility that cytochrome P450 enzymes (P450s) may catalyze TMP 
bioactivation. 
TMP is largely excreted unchanged in the urine. Several stable human urinary 
metabolites have previously been identified: the N-oxides, 1-NO-TMP and 3-NO-TMP, which 
are generated by oxidation of nitrogen atoms in the pyrimidine ring; the benzylic alcohol, Cα-
OH-TMP, formed via oxidation of the methylene bridge; and 3' and 4'-desmethyl-TMP resulting 
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from oxidative O-demethylation (Figure 1) (Brooks et al., 1973;  Sigel et al., 1973).  In vitro data 
generated by Damsten et al, suggest that multiple O-demethylation reactions may occur, 
resulting in up to three free hydroxyl groups on the benzylic ring (Damsten et al., 2008). 
In addition to the formation of these stable metabolites, evidence of TMP bioactivation 
has been demonstrated in vitro through the trapping of bioactivated TMP metabolites with small 
molecular weight thiols, such as NAC. TMP reactive metabolites are believed to form through 
both direct oxidation to an imino-quinone methide and via sequential secondary oxidation of 
primary, demethylated TMP metabolites to form a quinone methide (Damsten et al., 2008;  Lai et 
al., 1999).  Consistent with this in vitro evidence for TMP bioactivation, we detected six NAC-
TMP  conjugates  in the urine of children taking TMP-SMX (van Haandel et al., 2014). 
In vitro results have demonstrated that TMP bioactivation is catalyzed by P450s, 
although the specific enzymes involved in generating both the stable and reactive metabolites 
have not been well defined. Damsten et al described the formation of several NAC adducts and 
stable metabolites from TMP utilizing HLMs, rat liver microsomes, heterologously expressed 
P450 enzymes and P450 BM3 mutants. Based only on data from incubations containing 
heterologously expressed human P450s 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4, Damsten et al 
suggested that CYP1A2 and CYP3A4 were capable of forming the imino-quinone, while 
CYP2D6 was primarily responsible for catalyzing both the demethylation and subsequent 
secondary oxidation step to the quinone-methide species, and CYP3A4 catalyzed multiple TMP 
demethylation reactions leading to quinone methide intermediates (Damsten et al., 2008). 
Unfortunately, additional studies, such as correlation analyses with marker P450 activities in a 
panel of HLMs and inhibition of metabolite formation with P450 selective inhibitors, were not 
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performed to more fully characterize the quantitative importance of individual P450s. Formation 
of reactive intermediates, such as the imino-quinone and quinone methide species, are believed 
to be the initiating step in IADRs; thus, the aim of this study was to characterize the role of the 
P450s involved in the formation of TMP primary stable and reactive metabolites at 
therapeutically relevant concentrations of TMP to identify the enzymes most likely to contribute 
to TMP bioactivation at pharmacologically relevant exposures.  Defining the metabolic pathways 
leading to the bioactivation of TMP is a critical first step to better understand factors that may 
contribute to variability in reactive metabolite formation, and potentially, the risk of developing 
IADRs.  
MATERIALS AND METHODS 
Chemicals  
LC-MS Optima® grade water, methanol, and acetonitrile were purchased from Fisher 
Scientific (FairLawn, NJ, USA). EDTA, formic acid (LC-MS grade), glucose-6-phosphate 
dehydrogenase, magnesium chloride, N-acetyl-L-cysteine, NADP, potassium phosphate dibasic, 
potassium phosphate monobasic, TMP, α-Naphthoflavone, tranylcypromine, montelukast, 
sulfaphenazole, quinidine, 4-methylpyrazole, and danazol were obtained from Sigma Aldrich 
Chemical Co. (St. Louis, MO). Benzylnirvanol, and thiotepa were purchased from Toronto 
Research Chemicals (Toronto, Ontario, Canada).  Ketoconazole was obtained from Research 
Biochemicals International (Natick, MA). All reagents were reagent grade quality or higher. 1-
NO-TMP, 3-NO-TMP, 4'-desmethyl-TMP, Cα-OH-TMP, and Cα-NAC-TMP were custom 
synthesized by Artis-Chem Co. Ltd (Shanghai, China).  Purity of the standards was determined 
to be ≥98% by H-NMR, LCMS and LCUV at 214nm. 
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Human Liver Microsomes and cDNA-Expressed Enzymes  
A reaction phenotyping kit (Version 8; containing HLMs prepared from16 individuals; 4 
females, 12 males), pooled HLMs, and EasyCYP Bactosomes (manufactured by Cypex Ltd, 
Scotland, UK) were purchased from XenoTech, LLC (Lenexa, KS). The EasyCYP bactosomes 
included the following cDNA-expressed human P450 enzymes: P450s 1A1, 1A2, 1B1, 2A6, 
2A13, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5, 3A7 and 4A11. Microsomes were 
stored at -80°C and placed on ice prior to use.  
In vitro incubation conditions  
Standard in vitro enzyme incubations (200-µl) contained HLMs (20 µg of microsomal 
protein) or bacculovirus cDNA-expressed P450 enzymes (4 pmol), potassium phosphate buffer 
(50mM, pH 7.4), MgCl2 (3mM), EDTA (1mM), NAC (5mM) and TMP (0-500 µM) dissolved in 
water. Reactions were initiated by the addition of a NADPH-generating system consisting of 
NADP (1 mM), glucose 6-phosphate (1 U/ml), and glucose-6-phosphate dehydrogenase (5mM). 
Following the addition of NADPH, reactions were incubated in a shaking water bath at 37 ± 1°C 
for 0-30 minutes, and were terminated by the addition of 200 µL of ice-cold methanol. Protein 
was precipitated by centrifugation at 10,000 g for 10 minutes and an aliquot of supernatant was 
analyzed by HPLC/MS via direct injection.   
Preliminary experiments with TMP (0.5, 0.75, 1, 2.5, 5, 7.5, 10, 25, 50, 75, 100, 250, 
300, 400, 500 µM) and pooled HLMs (0.1, 0.5, 1.0 mg protein/ml) suggested that the rates of 
TMP metabolite formation were proportional to protein concentration (1.0 mg/ml) and time (60 
min).  Under these conditions, TMP biotransformation was less than 15%. Correlation 
experiments with HLMs were performed in triplicate with two replicate samples per condition.  
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Kinetic experiments and experiments performed with cDNA-expressed P450s were conducted in 
duplicate.  
Chemical-Inhibition Experiments  
Conversion of TMP (50 µM) to the primary metabolites of interest (1-NO-TMP, 3-NO-
TMP, 3'-desmethyl-TMP, 4'-desmethyl-TMP, Cα-OH-TMP, and Cα-NAC-TMP) by pooled 
HLMs was determined in the presence or absence of selective, competitive P450 inhibitors at 
four concentrations encompassing the denoted ranges including: α-Naphthoflavone (CYP1A2, 
0.15-5 µM), tranylcypromine (CYP2A6, 0.2-6 µM), thiotepa (CYP2B6, 5-150 µM), montelukast 
(CYP2C8, 0.15-5 µM), sulfaphenazole (CYP2C9, 0.3-10 µM), benzylnirvanol (CYP2C19, 0.3-
10 µM), quinidine (CYP2D6, 0.15-5 µM), 4-methylpyrazole (CYP2E1, 2-60 µM), danazol 
(CYP2J2, 0.02-0.6 µM), and ketoconazole (CYP3A4, 0.03-1 µM). These ranges of inhibitor 
concentrations were based on reported Ki values with the highest concentration of inhibitor 
approximately ~30 times Ki (range: Ki, 3 Ki, 10 Ki and 30 Ki). Inhibition experiments were 
conducted in triplicate with replicates. 
UPLC MS/MS Analysis  
Sample analysis was performed by UPLC MS/MS, as described by (van Haandel et al., 
2014).  Optimization of the analysis protocol included the injection of 3µL of sample to 
minimize band broadening, and the custom synthesis of reference compounds. The availability of 
reference standards allowed us to construct calibration curves for 1-NO-TMP, 3-NO-TMP, 4'-
desmethyl-TMP, Cα-OH-TMP, and Cα-NAC-TMP.  3'-desmethyl-TMP was quantitated from 
the 4'-desmethyl-TMP standard because of its structural similarity and due to the absence of 
available reference material. Calibration curves were constructed in MeOH quenched 
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incubations containing HLMs and 1, 3, 10, 30, 100, 300 or 400 µM concentrations of standard 
reference compounds. 
Data Analysis  
Correlation coefficients (r) between the rates of 1-NO-TMP, 3-NO-TMP, 3'-desmethyl-
TMP, 4'-desmethyl-TMP, Cα-OH-TMP, and Cα-NAC-TMP formation with the known 
expressed activities of P450 enzymes in the HLM reaction phenotype kit were determined using 
least-squares regression analysis to evaluate the relationship between enzymatic activity and 
metabolite formation.  Significance was determined by Pearson's regression analysis using a two-
tailed t-test with α = 0.05 (JMP® 10). Effects of the selective P450 inhibitors were determined by 
comparing the rate of individual metabolite formation as per cent of control by inhibitor 
concentration (Microsoft Excel 2007®). Rate calculations with the heterologously expressed 
enzymes were corrected for metabolite formation by microsomes containing vector only.  Data 
derived from kinetic incubation studies using HLMs and selected c-DNA expressed enzymes 
(CYP2C9 and 3A4) were analyzed by nonlinear regression to estimate Km and Vmax values. 
These data were visually inspected via Eadie–Hofstee and Lineweaver-Burk plots and 
subsequently fit to a one-enzyme Michaelis-Menten model (GraphFit 5; Erithacus Software Ltd., 
Surrey, UK).  
RESULTS 
Biotransformation of TMP by HLMs 
Incubations containing HLMs (pooled and from individual donors), TMP (5 and 50 µM) 
and NAC catalyzed the formation of six primary metabolites from TMP, namely, 1-NO-TMP, 3-
NO-TMP, 3'-desmethyl-TMP, 4'-desmethyl-TMP, Cα-OH-TMP, and Cα-NAC-TMP (Figure 1).  
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Figure 1. Metabolic scheme for the conversion of TMP to its primary oxidative metabolites. 
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Formation of these metabolites was consistent with our previous in vitro and in vivo observations 
(van Haandel et al., 2014). The 3'- and 4'-desmethyl-TMP were the most abundant metabolites 
present and accounted for approximately 65 and 25 percent of the total metabolite formation, 
respectively, regardless of substrate concentration. Of the remaining metabolites, only 1-NO-
TMP had an abundance approaching 5 per cent; each of the other minor metabolites constituted 
less than 2 per cent of the total metabolite formation (Figure 2). 
 
Figure 2. Variability in the rate of formation of primary trimethoprim formation.   
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Metabolism by flavin-containing monooxygenases (FMOs) was evaluated with heat inactivation 
of FMOs by heating pooled HLMs at 45°C for 5 minutes prior to incubations. There was no 
evidence of FMO contributing to primary TMP metabolism.   
The kinetics of formation for the six primary TMP metabolites were estimated in pooled 
adult HLMs and in microsomes containing cDNA-expressed CYP2C9 and CYP3A4 enzymes 
(Table 1).   
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Table 1. Estimated kinetic parameters for the formation of TMP primary metabolites in 
human liver microsomes and cDNA-expressed human P450 enzymes 
N.D. metabolite not detected 
I.D. insufficient data to determine kinetic parameters 
Value ± S.E. amicromolar, bpmol/mg protein per minute for pooled HLMs, cpmol/nmol P450/min for heterologously 
expressed enzymes, d µl/mg protein per minute for pooled HLMs, eµl /nmolP450 per minute for heterologously expressed 
  
    
 Km a Vmaxb,c Clintd,e 
 
Pooled HLMs 
  
 
 
 
1-NO-TMP 1050 ± 120 69 ± 6 0.07 
3-NO-TMP 690 ± 76 5 ± 0.3 0.007 
3'-desmethyl-TMP 647 ± 55 453 ± 25 0.70 
4'-desmethyl-TMP 482 ± 42 146 ± 7 0.30 
Cα-OH-TMP 2180 ± 400 108 ± 17 0.05 
Cα-NAC-TMP 1310 ± 160 18 ± 2 0.01 
    
CYP 2C9    
1-NO-TMP 531 ± 264 23.3 ± 6.87 0.044 
3-NO-TMP 428 ± 253 5.97 ± 1.95 0.014 
3'-desmethyl-TMP 1330 ± 400 2030 ± 470 1.53 
4'-desmethyl-TMP I.D. I.D. I.D. 
Cα-OH-TMP I.D. I.D. I.D. 
Cα-NAC-TMP I.D. I.D. I.D. 
    
CYP 3A4    
1-NO-TMP 971 ± 188 1320 ± 190 1.36 
3-NO-TMP N.D. N.D. N.D. 
3'-desmethyl-TMP 1470 ± 510  2060 ± 571 1.40 
4'-desmethyl-TMP 1040 ± 231 1430 ± 240 1.38 
Cα-OH-TMP 754 ± 122 1020 ± 110 1.35 
Cα-NAC-TMP 784 ± 143 137 ± 18 0.17 
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CYP2C9 and CYP3A4 were selected as it is thought that both significantly contribute to 
either direct bioactivation of TMP (Cα-NAC-TMP) or result in the abundant formation of 
primary metabolites (3' and 4'-desmethyl-TMP) that could potentially undergo further 
bioactivation to potential reactive species. The aqueous solubility of TMP limited final 
incubation concentrations to 500 µM or less. Direct plots of substrate concentration versus rate 
of TMP metabolite formation indicated that substrate saturation did not occur for the formation 
of any of the TMP primary metabolites (i.e., the plateau phase was not achieved). Although this 
precluded an accurate estimation of Km and Vmax parameters, Eadie-Hofstee plots were 
constructed for the available data. While there was a slight indication of substrate activation in 
the formation of Cα-OH-TMP, visual inspection of the Eadie-Hofstee plots for each of the six 
primary metabolites suggested that they could be fit to a single-enzyme Michaelis-Menten 
equation.  Data were then fit to a single enzyme model using the software, Grafit 5, to estimate 
the kinetic parameters Km and Vmax, which are shown in Table 1. Of note, all of the determined 
Km values for the six primary metabolites were above 450 µM, and as high as 2 mM, markedly 
higher than therapeutic concentrations of TMP observed in vivo. These conditions are such that 
the enzyme is not the rate-limiting factor for TMP biotransformation and ensures conditions for 
first-order kinetics. 
TMP N-oxidation (1 and 3-NO-TMP) 
Incubations with microsomes containing one of seventeen cDNA-expressed human P450 
enzymes were conducted at two TMP concentrations (5µM and 50 µM) to evaluate the ability of 
these enzymes to catalyze formation of the TMP N-oxides. The selected TMP concentrations 
were based on observed in vivo TMP Cmax.(Hoppu and Arjomaa, 1984;  Rylance et al., 1985)  
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Several heterologously expressed P450 enzymes, including CYP1A1, CYP1B1, CYP2C19, 
CYP3A4, CYP3A5 and CYP3A7, were capable of catalyzing 1-NO-TMP formation (Figure 3, 
panel A, 5µM data shown) while CYP1A1 and CYP1B1 were the heterologously expressed 
enzymes that catalyzed the highest rates of 3-NO-TMP formation. 
 
 
Figure 3.  N-oxidation of TMP to primary metabolites.  
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A panel of HLMs prepared from 16 individual donors and characterized for P450 and 
FMO activities using marker substrate reactions was examined for the ability to catalyze 
formation of TMP 1- and 3-N-oxides from TMP. Each of the microsomal preparations catalyzed 
the formation of both N-oxides to various degrees. At a substrate concentration of 5 µM, the rate 
of TMP N-oxide formation varied >6-fold;1-N-oxide formation (rates ± S.D.) ranged from 0.08 ± 
0.02 to 0.46 ± 0.20 pmol/mg protein/min whereas 3-N-oxide formation ranged from 0.01 ± 0.005 
to 0.08 ± 0.04 pmol/mg protein/min (Fig 2, panel A; Figure 3, panel B). Rates of TMP 1- and 3-
N-oxide formation for each of the microsomal samples increased proportionally (approximately) 
with a 10-fold increase in substrate concentration (50 µM; results not shown). The sample-to-
sample variation in the rates of 1-NO-TMP formation, correlated significantly (P< 0.01) with 
CYP2A6, CYP2C8, CYP2C9, and CYP3A4 activities whereas 3-NO-TMP formation correlated 
significantly with CYP1A2, CYP2C8 and CYP2C9 activities, but not with any other P450 or 
FMO activities (Table 2).  
  
14 
 
Table 2. Correlation analysis (r) of the relationship between the rates of TMP primary 
metabolite formation with the sample-to-sample variation in cytochrome P450 activities in 
human liver microsomes 
Cytochrome 
P450 
TMP 
Concentration  
1-NO-
TMP 
3-NO-
TMP 
 
3'-desmethyl-
TMP 
4'-desmethyl-
TMP Cα-OH-TMP 
Cα-NAC-
TMP 
1A2      (5uM) 0.444 0.710** 
 
0.578* 0.437 0.247 0.232 
           (50uM) 0.434 0.785** 
 
0.555* 0.409 0.235 0.221 
2A6      (5uM) 0.633** 0.435 
 
0.554* 0.566* 0.506* 0.493 
        (50uM) 0.587** 0.391 
 
0.512* 0.558* 0.488 0.488 
2B6      (5uM) 0.499* 0.145 
 
0.055 0.352 0.521* 0.510* 
 (50uM) 0.404 0.077 
 
0.000 0.316 0.459 0.457 
2C8      (5uM) 0.734** 0.884** 
 
0.750** 0.930** 0.302 0.292 
 (50uM) 0.612* 0.807** 
 
0.694** 0.867** 0.303 0.286 
2C9      (5uM) 0.742** 0.629** 
 
0.873** 0.759** 0.502* 0.499* 
       (50uM) 0.763** 0.616* 
 
0.888** 0.809** 0.537* 0.528* 
2C19    (5uM) 0.429 0.152 
 
0.145 0.239 0.500* 0.502* 
        (50uM) 0.379 0.152 
 
0.122 0.255 0.424 0.428 
2D6      (5uM) 0.110 0.167 
 
0.436 0.190 0.032 0.045 
        (50uM) 0.167 0.190 
 
0.481 0.251 0.063 0.055 
2E1      (5uM) 0.110 0.032 
 
0.226 0.000 0.190 0.192 
       (50uM) 0.197 0.000 
 
0.167 0.000 0.237 0.251 
2J2       (5uM) 0.510* 0.089 
 
0.438 0.390 0.548* 0.571* 
 (50uM) 0.540* 0.095 
 
0.514* 0.518* 0.573* 0.571* 
3A4/5  (5uM) 0.853** 0.148 
 
0.399 0.509* 0.991** 0.990** 
 (50uM) 0.905** 0.138 
 
0.466 0.632* 0.994** 0.995** 
4A11    (5uM) 0.389 0.512* 
 
0.458 0.489 0.164 0.179 
 (50uM) 0.423 0.544* 
 
0.511* 0.511* 0.217 0.219 
* significant at P < 0.05,  ** significant at P < 0.01 
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Inhibition studies were conducted to corroborate the identities of the enzymes involved in 
the formation of TMP N-oxides. As shown in Figure 3, panel C, the formation of 1-NO-TMP 
was inhibited markedly (greater than 20% inhibition) and in a concentration dependent manner 
by thiotepa (CYP2B6 inhibitor) and ketoconazole (CYP3A inhibitor). However, cDNA-
expressed CYP2B6 did not appear to catalyze 1-NO-TMP formation, nor was CYP2B6 activity 
correlated significantly with 1-NO-TMP formation in the panel of HLMs, suggesting that 
CYP2B6 may not be a major catalyst of this reaction.  α-Naphthoflavone (CYP1A inhibitor) was 
the only inhibitor examined that was found to inhibit 3-NO-TMP formation.  The other 
competitive P450 inhibitors resulted in little or no inhibition of either 1-NO-TMP or 3-NO-TMP 
formation supporting the assertion that 1-NO-TMP and 3-NO-TMP formation are catalyzed 
primarily by CYP3A4 and CYP1A2, respectively. 
TMP Demethylation (3' and 4'-desmethyl-TMP) 
Several heterologously expressed P450 isoforms examined in this study demonstrated the 
capability to catalyze the formation of 3' and 4'-desmethyl-TMP at 5µM TMP (Figure 4, panel 
A).  At a substrate concentration of 50µM, both CYP2C19 and CYP2D6 also catalyzed the 3'-
demethylation (data not shown). 
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Figure 4. Demethylation of TMP to primary metabolites.  
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The panel of HLMs was again used to examine demethylated TMP primary metabolite 
formation and variability was appreciated in rate formation among the sixteen different 
preparations (Figure 2, panel B; Figure 4, panel B). At a substrate concentration of 5µM, there 
was nearly 3-fold variation in 3'-desmethyl-TMP formation ranging from 1.5 ± 0.14 to 4.8 ± 0.49 
pmol/mg protein/min as compared to 5-fold variation in 4'-desmethyl-TMP formation ranging 
from 0.4 ± 0.02 to 2.3 ± 0.35 pmol/mg protein/min. The sample-to-sample variation in rate 
formation of 3' and 4'-desmethyl-TMP correlated (P< 0.01) with CYP2C8 and CYP2C9 
activities (Table 2).  
HLMs were incubated with 50 µM TMP and individual select P450 inhibitors at four 
concentrations (Figure 4, panel C). The formation of 3'-desmethyl-TMP was significantly 
inhibited by sulfaphenazole (CYP2C9 inhibitor) while only ketaconazole (CYP3A inhibitor) 
inhibited 4'-desmethyl-TMP metabolite formation.  The other competitive P450 inhibitors 
resulted in little or no inhibition.  Kinetics studies were subsequently performed with CYP3A 
and CYP2C9 to determine apparent Km and Vmax values (Table 1).  The apparent Km values for 
the formation of 3' and 4'-desmethyl-TMP by the heterologously expressed CYP2C9 and 
CYP3A4 were nearly 2-fold higher as compared to value calculated from the pooled HLMs. 
CYP2C9 was the primary pathway for 3'-desmethyl-TMP formation while CYP3A4 contributed 
to formation of all metabolites except 1-NO-TMP. These cumulative data suggested CYP2C9 
catalyzed 3'-desmethylation and CYP3A4 catalyzed 4'-desmethylation. 
TMP α-bridge Oxidation (Cα-OH-TMP and Cα-NAC-TMP) 
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The individual incubations with one of seventeen cDNA-expressed human P450 enzymes 
were conducted. CYP1A1 and CYP3A had the capability of catalyzing Cα-OH-TMP while  
CYP3A catalyzed Cα-NAC-TMP (Figure 5, panel A).  
 
 
Figure 5. Cα-oxidation of TMP to primary metabolites. 
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The panel of 16 HLMs was used to examine TMP metabolites formed by oxidative 
biotransformation at the α-bridge carbon.  Considerable variability in rate formation was 
observed among the sixteen different preparations (Figure 2, panel C; Figure 5, panel B). At the 
5µM substrate level, there was nearly 10-fold variation in Cα-OH-TMP ranging from 0.02 ± 
0.004 to 0.18 ± 0.03 pmol/mg protein/min and 17-fold variation in Cα-NAC-TMP ranging from 
0.007 ± 0.006 to 0.12 ± 0.07 pmol/mg protein/min formation, respectively. The sample-to-
sample variation in the rates of Cα-OH-TMP and Cα-NAC-TMP formation significantly 
correlated only with CYP3A4/5 (P < 0.01) (Table 2).  Furthermore, inhibition studies revealed 
that the formation of Cα-OH-TMP and Cα-NAC-TMP were significantly inhibited by 
ketoconazole (CYP3A inhibitor) (Figure 5, panel C).  
DISCUSSION 
Comprehensive characterization of the human P450 enzymes involved in TMP 
biotransformation has not been reported. Only one previous in vitro study (Damsten et al.) has 
provided insight into the enzymes involved in the formation of TMP metabolites. However, 
Damsten et al implicated the P450 enzymes involved in TMP metabolic pathways based solely 
on experiments conducted with heterologously expressed P450 enzymes, without additional 
kinetic, correlation or inhibition approaches that are needed to more completely determine the 
P450 enzymes involved in TMP biotransformation. Therefore, the present study was undertaken 
to further define the role that P450s play in the primary metabolism of TMP, with particular 
interest in the P450s responsible for metabolites observed in vivo, and especially the formation of 
Cα-NAC-TMP, as this is a postulated product of a reactive intermediate.  Furthermore, the 
primary metabolites, 3'-desmethyl and 4'-desmethyl-TMP, may serve as potential precursors to 
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reactive metabolites because both 3' and 4'-desmethyl-NAC-TMP adducts  have been identified 
in vitro and in vivo.(van Haandel et al., 2014) 
Many of the results from the current study corroborate the observations noted by 
Damsten et al.(Damsten et al., 2008).  CYP3A4 was identified as the major contributor to Cα-
NAC-TMP formation. We also identified CYP3A4 as the primary catalyst of Cα-NAC-TMP 
formation based on the results of correlation and inhibition studies, as well as the results of 
experiments with heterologously expressed P450 enzymes.  The evidence implicating CYP3A4 
as the primary catalyst of Cα-NAC-TMP formation is compelling: of the cDNA-expressed P450s 
examined, CYP3A4 catalyzed Cα-NAC-TMP formation, CYP3A4/5 activity was significantly 
correlated with the rate of Cα-NAC-TMP formation in the panel of HLMs, and the potent 
CYP3A inhibitor, ketoconazole, inhibited Cα-NAC-TMP formation in a concentration dependent 
manner. CYP3A4 also appears to be a major contributor of Cα-OH-TMP formation based on 
similar findings. Interestingly, CYP3A5 and CYP3A7, enzymes that are expressed in hepatic 
tissue (Hakkola et al., 1998) also catalyzed Cα-OH-TMP formation. CYP3A7 expression 
dominates in the fetal and neonatal liver, but rapidly decreases in activity postnatally while 
CYP3A5 expression is relatively low when compared to other P450s, but constant.(Hines, 2007) 
Thiotepa, a CYP2B6 inhibitor, inhibited Cα-OH-TMP formation in a concentration dependent 
manner, but to a lesser extent, than did the CYP3A inhibitor, ketoconazole.  Interestingly, 
heterologously expressed CYP2B6 did not appear to catalyze Cα-OH-TMP formation.  At the 
higher concentrations of the inhibitor, thiotepa, there is potential for less selectivity. This may 
result in partial inhibition of CYP3A leading to some reduction of metabolite formation not 
related to CYP2B6 activity.  
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CYP3A4 also appears to play a major role in the formation of the metabolite 4'-
desmethyl TMP. Although several heterologously expressed P450s, including 2C19, 2D6, 2J2 
and 3A4, demonstrated the capability to catalyze TMP 4'-demethylation , the only effective 
inhibitor of TMP 4-demethylation examined in HLMs was the CYP3A inhibitor, ketoconazole, 
which inhibited ~50% of TMP 4'-demethylase activity. Several P450 activities correlated with 4'-
desmethyl TMP formation in the panel of HLMs suggesting that although CYP3A4 appears to be 
a major contributor to 4'-desmethyl TMP formation, it is likely that other P450 enzymes may 
contribute to the formation of this metabolite at therapeutically relevant concentrations of TMP.  
Although heterologously-expressed CYP2D6 was the most prolific enzyme catalyzing 
the formation of the most abundant metabolite in our experiments, i.e., 3'-desmethyl TMP, 
corroborating the observation by Damsten et al.(Damsten et al., 2008) the CYP2D6 inhibitor 
quinidine caused no appreciable inhibition of TMP 3'-demethylation and the CYP2D6 activity of 
the HLM panel poorly correlated with rates of TMP 3'-demethylation (r = 0.481).  In contrast, 
heterologously expressed CYP2C9 catalyzed a much lower rate of TMP 3'-demethylation than 
did CYP2D6, but CYP2C9 appeared to play a major role in TMP 3'-demethylation in 
microsomal systems based on the observations that the CYP2C9 inhibitor, sulfaphenazole, 
substantially inhibited the formation of 3'-desmethyl TMP in pooled HLMs and the rate of 3'-
desmethyl TMP formation significantly correlated with CYP2C9 and CYP2C8 activities (which 
are co-regulated) in the panel of HLMs.  Because the activities of individual heterologously-
expressed P450s are dependent on a number of factors including co-expression of cytochrome 
P450 reductase and in some cases cytochrome b5, lipid membrane composition, etc., the use of 
heterologously expressed P450 enzymes usually is reserved for identification of isoforms 
capable of catalyzing a particular reaction.(Parkinson, 1996)  The current example provides a 
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case in point. Although CYP2D6 had the capability of 3'-demethylation with the heterologously 
expressed enzyme, CYP2D6 has a relative low content and activity as compared to other 
enzymatic activity, suggesting that in systems in which multiple enzymes are expressed (i.e. 
HLMs, in vivo), CYP2D6 activity may be overshadowed by other enzymes as the amount of 
CYP2D6 accounts for a relatively small portion of total P450 in the liver. (Venkatakrishnan et 
al., 2000)   
Our results suggest that P450s 2C9 and 3A4 are key enzymes in the biotransformation 
pathways responsible for metabolic clearance of TMP and the formation of reactive 
intermediates. SNPs present in CYP2C9 and CYP3A4 genes have the potential to contribute to 
inter-individual differences in drug disposition. (Kirchheiner and Brockmoller, 2005;  Werk and 
Cascorbi, 2014).  Hence, it is reasonable to expect that genotypic variation in CYP2C9 and 
CYP3A4 has the potential to alter the balance between bioactivation and detoxification impacting 
the relative abundance of reactive and stable TMP metabolites.  Further studies assessing in vivo 
TMP bioactivation are needed to better understand the extent and variability of TMP 
bioactivation in humans. As observed in our in vitro experiments, there was substantial 
variability in the rate of TMP Cα-carbon bioactivation; bioactivation and detoxification via Cα-
NAC-TMP formation varied by more than 15-fold. In addition, factors that determine which 
pathway TMP Cα-carbon oxidation intermediates commit to Cα-OH-TMP or Cα-NAC-TMP are 
currently unknown. The ratio of Cα-OH-TMP or of Cα-NAC-TMP varied between individual 
samples, indicating that additional factors are likely involved, otherwise one would expect a 
consistent ratio if a stoichiometric relationship was the only determining factor. Presumably, Cα-
OH-TMP and Cα-NAC-TMP share the same intermediate, yet factors determining whether a 
reactive intermediate is formed resulting in a NAC adduct versus a stable metabolite (Cα-OH-
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TMP) remain unclear. Further studies are necessary to identify determinants resulting in the 
variability of the imino-quinone intermediate formation as this may serve as a potential risk 
factor for IADR development. It is feasible that variability in CYP3A4 activity relative to other 
P450s determines the extent of primary TMP bioactivation in vivo and further studies are 
underway to assess the extent of primary TMP metabolism variability in vivo. Factors 
modulating activity of these contributing enzymes may affect the risk of ADRs.(Gill et al., 1999)   
Interestingly, previous data propose that SMX undergoes CYP2C9-mediated 
bioactivation to a hydroxylamine. This hydroxylamine undergoes subsequent auto-oxidation 
resulting in a reactive nitroso intermediate that can form haptenated cellular proteins capable of 
triggering a cellular immune response.(Callan et al., 2009;  Naisbitt et al., 2002)  The results of 
the present study demonstrate that CYP2C9 contributes to formation of the most abundant 
primary TMP metabolite (3'-desmethyl TMP) in vitro. Consequently, the potential exists for 
either TMP or SMX to directly influence the extent of metabolism and possible bioactivation of 
the other component when administered concomitantly at a combined fixed dose. For example, 
an individual who extensively metabolizes TMP to the 3’-desmethyl TMP metabolite could 
conceivably experience a relative decrease in the amount of SMX hydroxylamine that is formed. 
There is no evidence of mechanism based inhibition of either trimethoprim or sulfamethoxazole; 
however the extent of metabolism potentially impacting bioactivation of the other component has 
not been evaluated. (Wen et al., 2002) 
Our current work only characterizes the role that P450 enzymes play in the primary 
biotransformation pathways of TMP. Detection of 4'-desmethyl TMP glutathione or NAC 
adducts in vitro and in vivo implies that 4'-desmethyl TMP undergoes a further oxidation step 
24 
 
presumably through a quinine methide intermediate (Leblanc et al., 2010;  van Haandel et al., 
2014).  Subsequent bioactivation of a stable primary metabolite has been attributed to potential 
additional pathways resulting in IADRs with commonly implicated drugs such as phenytoin and 
carbamazepine.(Cuttle et al., 2000;  Pearce et al., 2008)    
In summary, our in vitro studies implicate CYP3A4 as the predominant cytochrome P450 
enzyme involved in the direct formation of a reactive metabolite (i.e. Cα-NAC-TMP) from TMP.  
In addition, CYP 3A4 plays a major role in the generation of 4'-desmethyl TMP, which is 
believed to be a precursor in a second bioactivation pathway. Characterization of the isoforms 
responsible for secondary TMP bioactivation is critical to understand all potential sources of 
inter-individual variation involved in the generation of reactive intermediates capable of forming 
haptenated proteins.  Although TMP has historically been overlooked as a probable contributor 
of IADRs; evidence of TMP bioactivation suggests that it too may contribute to these well-
recognized, unpredictable reactions associated with TMP-SMX. Therefore, a better 
understanding of bioactivation may potentially providing insight in identifying those at risk of 
developing an IADR prior to its occurrence.   
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APPENDIX: 
Figure 1. Metabolic scheme for the conversion of TMP to its primary oxidative metabolites. 
Figure 2. Variability in the rate of formation of primary trimethoprim formation. A panel of 
commercially available HLMs prepared from 16 individual donors was examined to determine 
the ability of HLMs to catalyze primary TMP metabolites. Sample to sample variability in 
metabolite formation is demonstrated: Panel A exhibits TMP N-oxidation (1 and 3-NO-TMP), 
Panel B shows TMP Demethylation (3' and 4'-desmethyl-TMP), and TMP Cα-oxidation (Cα-
OH-TMP and Cα-NAC-TMP) is shown in Panel C.  
 Figure 3.  N-oxidation of TMP to primary metabolites. Panel A: 1- and 3-NO-TMP formation 
by human cDNA-expressed P450 enzymes. TMP (5 µM) was incubated with cDNA-expressed 
P450 enzymes as described under materials and methods. Rates shown are corrected for rates 
from microsomes containing vectors alone. Each bar represents the mean of the duplicate 
incubations. Panel B: Sample-to-sample variation in the rates of TMP 1- and 3 N-oxidation by 
HLMs at a substrate concentration of 5 µM. Each bar represents the mean of the triplicate 
experiments ± S.D.  Panel C: Effects of various P450 isoform-selective inhibitors on the 
formation of 1- and 3-NO-TMP by pooled HLMs at a substrate concentration of 50 µM, as 
described under Material and Methods. Each bar represents the mean of the triplicate 
incubations. Uninhibited mean rates of 1- and 3-NO-TMP formation were 205 and 40 pmol/mg 
protein/min, respectively. 
Figure 4. Demethylation of TMP to primary metabolites. Panel A: 3' and 4'-desmethyl-TMP 
formation by human cDNA-expressed P450 enzymes. TMP (5 µM) was incubated with cDNA-
expressed P450 enzymes as described under materials and methods. Rates shown are corrected 
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for rates from microsomes containing vectors alone. Each bar represents the mean of the 
duplicate incubations. Panel B: Sample-to-sample variation in the rates of TMP 3' and 4'-
desmethyl-TMP by HLMs at a substrate concentration of 5 µM. Each bar represents the mean of 
the triplicate experiments ± S.D.  Panel C: Effects of various P450 isoform-selective inhibitors 
on the formation of 3' and 4'-desmethyl-TMP by pooled HLMs at a substrate concentration of 50 
µM, as described under Material and Methods. Each bar represents the mean of the triplicate 
incubations. Uninhibited rates of 3' and 4'-desmethyl-TMP formation were 1202 and 731 
pmol/mg protein/min, respectively. 
 Figure 5. Cα-oxidation of TMP to primary metabolites. Panel A: Cα-OH-TMP and Cα-NAC-
TMP formation by human cDNA-expressed P450 enzymes. TMP (5 µM) was incubated with 
cDNA-expressed P450 enzymes as described under materials and methods. Rates shown are 
corrected for rates from microsomes containing vectors alone. Each bar represents the mean of 
the duplicate incubations. Panel B: Sample-to-sample variation in the rates of Cα-OH-TMP and 
Cα-NAC-TMP formation by HLMs at a substrate concentration of 5 µM. Each bar represents the 
mean of the triplicate experiments ± S.D.  Panel C: Effects of various P450 isoform-selective 
inhibitors on the formation of Cα-OH-TMP and Cα-NAC-TMP by pooled HLMs at a substrate 
concentration of 50 µM, as described under Material and Methods. Each bar represents the mean 
of the triplicate incubations. Uninhibited rates of Cα-OH-TMP and Cα-NAC-TMP formation 
were 116 and 54 pmol/mg protein/min, respectively. 
